Evidence-based assessment of treatment options for children with IgA nephropathies

Pediatric Nephrology

Volumn 16, Issue 2, 2001, Pages 156-167

  Wyatt, R J ^a   Hogg, Ronald J ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

Evidence based assessment; Henoch Sch nlein purpura nephritis; IgA nephropathy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL;

ANAPHYLACTOID PURPURA; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; PRIORITY JOURNAL; REVIEW; TONSILLECTOMY; TREATMENT OUTCOME;

ADULT; CHILD; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 0035140468     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670000517     Document Type: Review

References (78)

1. Evidence-based medicine
2. A new approach to teaching the practice of medicine
3. Report of the Canadian Hypertension Society Consensus Conference. I. Introduction
4. Evidence based medicine: What it is and what it isn't
5. Management of glomerulonephritis
6. Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and adult Japanese
7. IgA nephropathy: Long-term prognosis for pediatric patients
8. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: Survey of the recent literature
9. Management of IgA nephropathy: Evidence-based recommendations
10. Idiopathic recurrent macroscopic hematuria and mesangial IgA-IgG deposits in children (Berger's disease)
11. Idiopathic mesangial IgA-glomerulonephritis in childhood. Description of 19 pediatric cases and review of the literature
12. IgA nephropathy (Berger's disease) - A clinicopathologic study in children
13. Berger's disease in children. Natural history and outcome
14. IgA nephropathy in children from Japan. Clinical and pathological features
15. Prognostic indicators in children with IgA nephropathy - A report of the Southwest Pediatric Nephrology Study Group
16. Rules of evidence and clinical recommendations on the use of antithrombotic agents
17. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial
18. Alternate-day prednisone therapy in IgA. Preliminary analysis of a prospective, randomized, controlled trial
19. Corticosteroids in IgA nephropathy
20. Glomerular morphology, natural history and treatment of children with IgA-IgG mesangial nephropathy
21. Treatment of severe IgA nephropathy in children
22. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis
23. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy
24. Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: Effects against deterioration of renal function. A Biomedicine and health research concerted action
25. Alternate-day prednisone therapy in children with IgA-associated nephritis
26. Treatment of IgA nephropathy in children: Efficacy of alternate-day oral prednisone
27. Glomerular macrophages predict steroid response in childhood IgA nephropathy
28. Age-related histologic alterations after prednisolone therapy in children with IgA nephropathy
29. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy
30. Rapidly progressive IgA nephropathy
31. Does methylprednisolone pulse therapy deteriorate the course of rapidly progressive IgA nephropathy?
32. Early start of intensive therapy in malignant form of IgA nephropathy
33. Primary IgA nephropathies in children: Prognosis and treatment
34. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy
35. Platelet membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet
36. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells
37. A controlled trial of fish oil in IgA nephropathy
38. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis
39. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two-year prospective trial
40. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study
41. Fish oil therapy for IgA nephropathy: Efficacy and interstudy variation
42. Treatment of hypertension
43. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy
44. Tonsillectomy decreases the synthesis of polymeric IgA by blood lymphocytes and clinical activity in patients with IgA nephropathy
45. Tonsils in IgA nephropathy
46. Clinical and immunological study of IgA nephropathy before and after tonsillectomy
47. Long-term effects of intensive therapy combined with tonsillectomy in patients with IgA nephropathy
48. Chronic tonsillitis and IgA nephropathy. Clinical study of patients with and without tonsillectomy
49. Clinical study of chronic tonsillitis with IgA nephropathy treated by tonsillectomy
50. Tonsillectomy does not prevent a progressive course in IgA nephropathy
51. Effects of tonsillectomy on juvenile nephritis, purpura nephritis and chronic and persistent glomerulonephritis
52. Chronic tonsillitis and IgA nephropathy
53. Effect of and indication for tonsillectomy in IgA nephropathy
54. Effects of tonsillectomy in children with IgA nephropathy, purpura nephritis, or other chronic glomerulonephritides
55. Syndrome nephrotique de l'enfant a lesions glomérulaires minims, avec depôts mésangiaux d'IgA
56. The nephritic syndrome in IgA glomerulonephritis: Response to corticosteroid therapy
57. Mesangial IgA deposits with steroid responsive nephrotic syndrome: Probable minimal lesion nephrosis
58. Dramatic response to corticosteroid therapy of nephrotic syndrome associated with IgA nephropathy
59. Association of IgA nephropathy with steroid-responsive nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group
60. Steroid-sensitive nephritic syndrome with mesangial IgA deposits: A separate entity?
61. Mesangial IgA nephropathy and idiopathic nephrotic syndrome
62. Immunopathological findings in idiopathic nephrosis: Clinical significance of glomerular "immune deposits"
63. Incidence of renal complications in Schönlein-Henoch purpura syndrome in dependence on an early administration of steroids
64. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura
65. Corticosteroid therapy does not prevent nephritis in Henoch-Schönlein purpura
66. Renal involvement in Henoch-Schönlein purpura: A multivariate analysis of prognostic factors
67. Anaphylactoid purpura in childhood: Natural history and immunopathology
68. Anaphylactoid purpura: Characteristics of 16 patients who progressed to renal failure
69. Long-term follow-up of childhood Henoch-Schönlein nephritis
70. Henoch-Schönlein nephritis: Long-term prognosis of unselected patients
71. Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population
72. Prognosis of Henoch-Schönlein purpura nephritis in children
73. Effective therapy for Henoch-Schönlein purpura nephritis with prednisone and azathioprine: A clinical and histopathologic study
74. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis
75. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis
76. Multiple combined therapy for severe Henoch-Schönlein nephritis in children
77. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children
78. Clinical outcome of Schönlein-Henoch purpura nephritis in children